You just read:

BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019

News provided by

BerGenBio ASA

02 Jun, 2019, 14:35 BST